RecruitingHepatocellular Carcinoma
SBRT With Atezo/Bev for HCC
Eligible age
18–99 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)
Sponsor: Abramson Cancer Center at Penn Medicine
You may qualify if…
- ✓ Subjects must have hepatocellular carcinoma (HCC) that is not amenable to curative-intent surgical or ablation (where surgery or ablation are not indicated due to disease extent, co-morbidities, or other technical reasons) and systemic therapy is indicated.
You may not qualify if…
- ✕ \-
Where it's recruiting
Pennsylvania
Philadelphia
Source: ClinicalTrials.gov · NCT05488522 · last updated 2026-02-20